Please login to the form below

Not currently logged in
Email:
Password:

New Accounts, June, 2009, Advertising

New pharmaceutical account wins notified to us by the winning agency for the period April 2009 and June 2009 inclusive:

New pharmaceutical account wins notified to us by the winning agency for the period April 2009 and June 2009 inclusive:

       

CLIENT

PRODUCT

THERAPEUTIC AREA

WINNING AGENCY

Abbott Laboratories/ International
Kaletra
Virology
Grace Agency
ApaTech Actifuse Bone graft material Fleishman-Hillard International
Bausch & Lomb Ocuvite Ophthalmology (OTC)
Pulsar Healthcare Communications
Bausch & Lomb PreserVision Ophthalmology (OTC)
Pulsar Healthcare Communications
Baxter Healthcare Renal Division Home dialysis Renal
Life
Boehringer Ingelheim
New product launch
Women's Health
MSA Market Media
Bupa Home Healthcare N/A Corporate Pulsar Healthcare Communications
CarieScan CarieScan Dentistry Pulsar Healthcare Communications
Gilead
Early treatment project
HIV
Life
IS Pharma         Haemopressin/ Variquel (Europe) Hepatology Pulsar Healthcare Communications
Novo Nordisk
NovoSeven corporate
Haemophilia
Life
Reckitt Benckiser Nurofen Analgesia Hive
Spectrum Thea        Virgan Ophthalmology Pulsar Healthcare Communications
Teva Ireland Naramerg CNS Pulsar Healthcare Communications

  

Please note that inclusion in this table does not necessarily indicate exclusivity and other agencies may not be involved with some of the products listed in other ways, or in domestic, overseas or international markets.

To submit an entry for New Accounts, email new_accounts@pmlive.com

7th July 2009

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Spirit, an OPEN Health Company

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...